Next-gen GLP-1s could raise the ceiling
Ibsen DB, Steur M, Imamura F, Overvad K, Schulze MB, Bendinelli B, et al
Therefore, any GLP-1 active ingredient used in compounded products must be the same as that which is used in an authorized product (biologically derived, as determined by Health Canada) or listed in a recognized Pharmacopoeia
Those taking higher doses may notice more significant changes after missing an injection than those on lower doses
These systems can be designed to be paintable for easy application on the epicardial surface or as microneedle patches for sequential, multi-drug delivery aligned with the pathological phases of MIRI (Lee et al., 2024